

mRNA Vaccine and Therapeutics- Market Insights, Competitive Landscape, and Market Forecast - 2027

Market Report (3-5 days) | 2023-04-01 | 100 pages | DelveInsight

AVAILABLE LICENSES:

- Single User Price \$2750.00
- Site License Price \$5500.00
- Enterprise Price \$8250.00

Report description:

mRNA Vaccines And Therapeutics Market By Vaccine Type (Self-Amplifying Mrna Based Vaccines And Conventional Non-Amplifying mRNA Based Vaccines), By End-User (Hospitals And Clinics, Research And Development Organizations, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the rising demand for protection against sudden pandemic outbreaks and the increasing patient pool associated with infectious diseases across the globe, among others

The global mRNA Vaccines and Therapeutics market was valued at USD 71,263 million in 2022, growing at a CAGR of -34.01% during the forecast period from 2023 to 2028. The demand for mRNA vaccines and therapeutics is primarily being boosted due to the rising demand for protection against sudden pandemic outbreaks, the increasing patient pool associated with infectious diseases across the globe, the rise in the number of ongoing clinical trials for various indications among others, leading to a positive impact on the market growth during the forecast period from 2023-2028.

mRNA Vaccines And Therapeutics Market Dynamics:

The rising demand for vaccines to protect against sudden pandemic outbreaks such as COVID-19 and to induce immunity among the global population is one of the key factors driving the overall growth of the mRNA vaccine and therapeutics market. COVID-19 vaccines are highly effective at protecting people from getting seriously ill, being hospitalized, and even dying. The mRNA vaccines, owing to their new technology are deemed to be safe and help to create immunity against infectious agents such as viruses, creating an antibody response without experiencing any potentially severe illness.

The viruses constantly change over time, which can lead to the emergence of variants that might have newer characteristics. The vaccines thereby continue to immunize people from developing serious illnesses.

In August 2021, the U.S. Food and Drug Administration (FDA) approved the mRNA COVID-19 vaccine by Pfizer-BioNTech. It was marketed under the name of Comirnaty for the prevention of COVID-19 disease in individuals aged 12 years or older.

In addition, the increasing adoption of mRNA vaccines and therapeutics, owing to the growing awareness, research activities, and funding has allowed big firms to potentially increase their innovative approach, to protect against future disease outbreaks, which is thereby anticipated to propel the overall growth of the mRNA vaccines and therapeutics market in the upcoming years.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

However, strict regulatory approvals and the presence of pre-existing vaccines with alternative technologies in the market among others may restrict the mRNA vaccines and therapeutics market growth during the given forecast period.

The COVID-19 pandemic had a positive impact on the market growth of mRNA vaccines and therapeutics as during the peak corona period when coronavirus cases were surging drastically, health institutions and companies were intensely involved in research activities for the development of mRNA vaccines as soon as possible, also receiving funding from various multinational firms and governments to facilitate the vaccine development process. In the initial stages, the shortage of raw and packaging materials, consumables, and equipment owing to lockdown impositions, border closures, and others hindered the production of mRNA vaccines. However, robust research and development activities on the COVID-19 vaccine including those based on mRNA were being conducted by the major companies. Considering the challenge posed by emerging diseases globally on life and the economy owing to their potential to turn into global pandemics (e.g., COVID-19, and others), the research and development of mRNA vaccines are essential as they act as a preventive countermeasure for these diseases. Thereby, post-pandemic arena owing to the introduction of vaccines, resumption of activities in the healthcare and pharmaceutical sector, and rising focus by the governments on strategized plans for further outbreaks, the mRNA vaccine market is expected to grow exponentially during the forecast period.

mRNA Vaccines And Therapeutics Market Segment Analysis:

mRNA Vaccines and Therapeutics market by Vaccine Type (Self-Amplifying mRNA Based Vaccines and Conventional Non-Amplifying mRNA Based Vaccines), End-User (Hospitals and Clinics, Research and Development Organizations, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the vaccine type segment of the mRNA vaccines and therapeutics market, the self-amplifying mRNA-based vaccines category is expected to amass significant revenue share in the year 2022. This is primarily owing to the wide number of advantages and the increasing number of research and development activities in the sector on self-amplifying mRNA-based vaccines.

Self-amplifying mRNA-based vaccines help in easy storage, along with lower costs because its "self-amplifying" design allows them for smaller doses. A self-amplifying mRNA vaccine ideally would replace the two primary doses given during the time of pandemics, giving it an even clearer benefit over its conventional relatives. A booster dose, months later might still be warranted, as is encouraged now for the current mRNA vaccines. The self-amplifying mRNAs could also lead to more durable immune responses.

In June 2022, Genovva Biopharmaceuticals launched its mRNA vaccine for COVID-19 named, Gemcovac-19 which can be stored at temperatures between 2°C and 8°C, and uses the mechanism of self-amplification.

Therefore, owing to the above-mentioned factors, the self-amplifying mRNA-based vaccines category is expected to witness considerable growth, eventually contributing to the overall growth of the global mRNA vaccines and therapeutics market during the forecast period from 2023-2028.

North America is expected to dominate the overall mRNA Vaccines And Therapeutics Market:

Among all the regions, North America is estimated to account for the largest share of the mRNA vaccines and therapeutics market in the year 2022. This domination is owing to the increasing prevalence of infectious diseases, such as COVID-19 infection, new and growing cases of monkeypox, and recent vaccine development activities in the North America region.

According to the CDC (2022), the US reported 6,617 cases of monkeypox till August 2022. The presence of such a huge patient population in the US may trigger research activities by big companies in the region. Along with the recent rise in the cases of monkeypox, vaccine development for monkeypox is further expected to drive the market demand for mRNA vaccines during the forecast period. Additionally, various mRNA vaccine development activities for various diseases in the North America region are also anticipated to expand the vaccine market during the given forecast period.

For example, in August 2021, US FDA announced the first approval of a COVID-19 mRNA vaccine manufactured by Pfizer and BioNTech known as the Pfizer-BioNTech COVID-19 vaccine for individuals 12 years of age and above.

Additionally, as per statistics by the Clinical Trials Government, around 150 mRNA vaccine clinical trials were registered in the United States involving biopharmaceuticals in 2022, thus the increasing number of clinical trials for mRNA vaccines in the region is anticipated to drive the growth of the market.

Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

America mRNA vaccines and therapeutics market during the forecast period.

mRNA Vaccines And Therapeutics Market Key Players:

Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Charoen Pokphand Group, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc, and others.

Recent Developmental Activities in the mRNA Vaccines And Therapeutics Market:

- In March 2023, Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 4 years of age at least 2 months after completion of primary vaccination with three doses of the Pfizer-BioNTech COVID-19 Original Vaccine. The bivalent vaccine is also authorized in this age group as the third dose of a three-dose-primary series.
- In December 2022, Biopharmaceutical New Technologies (BioNTech) SE, a global leader in mRNA vaccines, announced that the first subject was dosed in Phase 1 clinical research study with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1. The first-in-human trial evaluates the safety, tolerability, and immunogenicity of BNT163.
- In September 2022, Pfizer Inc. announced that the first participants have been dosed in a pivotal Phase 3 clinical trial to evaluate the efficacy, safety, tolerability, and immunogenicity of the company's quadrivalent modified influenza mRNA vaccine candidate in approximately 25,000 healthy U.S. adults.

Key Takeaways from the mRNA Vaccines And Therapeutics Market Report Study

- Market size analysis for current mRNA Vaccines and Therapeutics market size (2022), and market forecast for 5 years (2023-2028)
- The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the mRNA Vaccines and Therapeutics market.
- Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the global mRNA Vaccines and Therapeutics market.
- Various opportunities available for the other competitor in the mRNA Vaccines and Therapeutics market space.
- What are the top-performing segments in 2022? How these segments will perform in 2028.
- Which are the top-performing regions and countries in the current mRNA Vaccines and Therapeutics market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for mRNA Vaccines and Therapeutics market growth in the coming future?

- Target Audience who can be benefited from this mRNA Vaccines And Therapeutics Market Report Study
- mRNA Vaccines and Therapeutics products providers
- Research organizations and consulting companies
- mRNA Vaccines and Therapeutics-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders dealing in mRNA Vaccines and Therapeutics
- Various end-users who want to know more about the mRNA Vaccines and Therapeutics market and the latest innovation and developments in the mRNA Vaccines and Therapeutics market.

Frequently Asked Questions for the mRNA Vaccines And Therapeutics Market:

1. What are mRNA Vaccines and Therapeutics?

mRNA vaccines are a new type of vaccine that use a molecule called messenger RNA (mRNA) rather than part of an actual bacteria or virus. Messenger RNA is a type of RNA that is necessary for protein production. Once cells finish making a protein,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

they quickly break down the mRNA. mRNA from vaccines does not enter the nucleus and does not alter DNA.

2. What is the market for Global mRNA Vaccines and Therapeutics?

The global mRNA Vaccines and Therapeutics market was valued at USD 71,263 million in 2022, growing at a CAGR of -34.01% during the forecast period from 2023 to 2028.

3. What are the drivers for the global mRNA Vaccines and Therapeutics market?

The demand for mRNA Vaccines and Therapeutics is expected to increase substantially due to the rising demand for protection against sudden pandemic outbreaks, the increasing patient pool associated with infectious diseases across the globe, rise in the number of ongoing clinical trials for various indications among others, leading to a positive impact on the market growth during the forecast period from 2023-2028.

4. Who are the key players operating in the global mRNA Vaccines and Therapeutics market?

Some of the key market players operating in the mRNA Vaccines and Therapeutics market include Pfizer Inc., BioNTech SE, Moderna, Inc., Genovra Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Charoen Pokphand Group, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc, and others.

5. Which region has the highest share in the mRNA Vaccines and Therapeutics market?

North America is expected to dominate the overall mRNA Vaccines and Therapeutics market during the forecast period from 2023-2028. This can be ascribed to the increasing prevalence of infectious diseases, such as COVID-19 infection, new and growing cases of monkeypox, and recent vaccine development activities in the North America region.

Table of Contents:

1. mRNA Vaccines and Therapeutics Market Report Introduction
2. mRNA Vaccines and Therapeutics Market Executive Summary
 - 2.1. Scope of the Study
 - 2.2. Market at Glance
 - 2.3. Competitive Assessment
3. Regulatory Analysis
 - 3.1. The United States
 - 3.2. Europe
 - 3.3. Japan
 - 3.4. China
4. mRNA Vaccines and Therapeutics Market Key Factors Analysis
 - 4.1. mRNA Vaccines and Therapeutics Market Drivers
 - 4.1.1. Rising demand for protection against sudden pandemic outbreaks
 - 4.1.2. Increasing patient pool associated with infectious diseases across the globe
 - 4.1.3. Rise in the number of ongoing clinical trials for various indications
 - 4.2. mRNA Vaccines and Therapeutics Market Restraints and Challenges
 - 4.2.1. Strict regulatory approvals
 - 4.2.2. Presence of pre-existing vaccines with alternative technologies in the market
 - 4.3. mRNA Vaccines and Therapeutics Market Opportunities
 - 4.3.1. Increasing research and development activities on mRNA vaccines
 - 4.3.2. The increasing number of investments and funding by governments and market players
5. mRNA Vaccines and Therapeutics Market Porter's Five Forces Analysis
 - 5.1. Bargaining Power of Suppliers
 - 5.2. Bargaining Power of Consumers
 - 5.3. Threat of New Entrants
 - 5.4. Threat of Substitutes

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.5. Competitive Rivalry
- 6. COVID-19 Impact Analysis on mRNA Vaccines and Therapeutics Market
- 7. mRNA Vaccines and Therapeutics Market Layout
 - 7.1. By Vaccine Type
 - 7.1.1. Self-amplifying mRNA-Based Vaccines
 - 7.1.2. Conventional Non-Amplifying mRNA-Based Vaccines
 - 7.2. By End-User
 - 7.2.1. Hospitals and Clinics
 - 7.2.2. Research and Development Organizations
 - 7.2.3. Others
 - 7.3. By Geography
 - 7.3.1. North America mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.1.1. United States mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.1.2. Canada mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.1.3. Mexico mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.2. Europe mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.2.1. France mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.2.2. Germany mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.2.3. United Kingdom mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.2.4. Italy mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.2.5. Spain mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.2.6. Rest of Europe mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.3. Asia-Pacific mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.3.1. China mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.3.2. Japan mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.3.3. India mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.3.4. Australia mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.3.5. South Korea mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.3.6. Rest of Asia-Pacific mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.4. Rest of the World (RoW) mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.4.1. Middle East mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.4.2. Africa mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
 - 7.3.4.3. South America mRNA Vaccines and Therapeutics Market Size in USD million (2020-2028)
- 8. mRNA Vaccines and Therapeutics Market Company and Product Profiles
 - 8.1. Pfizer Inc.
 - 8.1.1. Company Overview
 - 8.1.2. Company Snapshot
 - 8.1.3. Financial Overview
 - 8.1.4. Product Listing
 - 8.1.5. Entropy
 - 8.2. BioNTech SE
 - 8.2.1. Company Overview
 - 8.2.2. Company Snapshot
 - 8.2.3. Financial Overview
 - 8.2.4. Product Listing
 - 8.2.5. Entropy
 - 8.3. Moderna Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
- 8.4. Gennova Biopharmaceuticals Limited
 - 8.4.1. Company Overview
 - 8.4.2. Company Snapshot
 - 8.4.3. Financial Overview
 - 8.4.4. Product Listing
 - 8.4.5. Entropy
- 8.5. GSK plc.
 - 8.5.1. Company Overview
 - 8.5.2. Company Snapshot
 - 8.5.3. Financial Overview
 - 8.5.4. Product Listing
 - 8.5.5. Entropy
- 8.6. Daiichi Sankyo
 - 8.6.1. Company Overview
 - 8.6.2. Company Snapshot
 - 8.6.3. Financial Overview
 - 8.6.4. Product Listing
 - 8.6.5. Entropy
- 8.7. Arcturus
 - 8.7.1. Company Overview
 - 8.7.2. Company Snapshot
 - 8.7.3. Financial Overview
 - 8.7.4. Product Listing
 - 8.7.5. Entropy
- 8.8. Boehringer Ingelheim International GmbH
 - 8.8.1. Company Overview
 - 8.8.2. Company Snapshot
 - 8.8.3. Financial Overview
 - 8.8.4. Product Listing
 - 8.8.5. Entropy
- 8.9. Ethris GmbH
 - 8.9.1. Company Overview
 - 8.9.2. Company Snapshot
 - 8.9.3. Financial Overview
 - 8.9.4. Product Listing
 - 8.9.5. Entropy
- 8.10. CureVac SE
 - 8.10.1. Company Overview
 - 8.10.2. Company Snapshot
 - 8.10.3. Financial Overview
 - 8.10.4. Product Listing
 - 8.10.5. Entropy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.11. AIM Vaccine Corporation
 - 8.11.1. Company Overview
 - 8.11.2. Company Snapshot
 - 8.11.3. Financial Overview
 - 8.11.4. Product Listing
 - 8.11.5. Entropy
- 8.12. Charoen Pokphand Group
 - 8.12.1. Company Overview
 - 8.12.2. Company Snapshot
 - 8.12.3. Financial Overview
 - 8.12.4. Product Listing
 - 8.12.5. Entropy
- 8.13. Argos Therapeutics Inc.
 - 8.13.1. Company Overview
 - 8.13.2. Company Snapshot
 - 8.13.3. Financial Overview
 - 8.13.4. Product Listing
 - 8.13.5. Entropy
- 8.14. Sanofi
 - 8.14.1. Company Overview
 - 8.14.2. Company Snapshot
 - 8.14.3. Financial Overview
 - 8.14.4. Product Listing
 - 8.14.5. Entropy
- 8.15. Kernal Biologics Inc.
 - 8.15.1. Company Overview
 - 8.15.2. Company Snapshot
 - 8.15.3. Financial Overview
 - 8.15.4. Product Listing
 - 8.15.5. Entropy
- 9. KOL Views
- 10. Project Approach
- 11. About DelveInsight
- 12. Disclaimer & Contact Us

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

mRNA Vaccine and Therapeutics- Market Insights, Competitive Landscape, and Market Forecast - 2027

Market Report (3-5 days) | 2023-04-01 | 100 pages | DelveInsight

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2750.00
	Site License Price	\$5500.00
	Enterprise Price	\$8250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

